Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:07 PM ET 8-K
Financial Results Resmed Inc RMD

Resmed Financial Results

ResMed reported Q1 fiscal year 2027 revenue of $1.4 billion, a 6% increase driven by global demand for sleep and breathing health solutions. The company returned over $1 billion to shareholders through dividends and share repurchases during the quarter, supported by strong free cash flow and the divestiture of MatrixCare.

Term
Q1 2027

“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.”

Mick Farrell, Resmed’s Chairman and CEO

“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”

Mick Farrell, Resmed’s Chairman and CEO
4:06 PM ET 8-K
Financial Results Healthcare Realty Trust Inc HR

Healthcare Realty Trust Financial Results

Healthcare Realty Trust reported Q3 2026 financial results, including a Normalized FFO of $0.42 per share and same-store cash NOI growth of 5.1%. The company increased its full-year 2026 Normalized FFO guidance to a range of $1.65 to $1.67 per share. Operational highlights include 1.5 million square feet of lease executions and $211 million in joint venture acquisitions with KKR.

4:06 PM ET 8-K
Financial Results Amazon Com Inc AMZN

Amazon Com Financial Results

Amazon reported third-quarter 2026 net sales of $201.9 billion, up 12% year-over-year, driven by 39% growth in its AWS segment. Operating income reached a record $28.1 billion with a 13.9% margin, though net income slightly decreased to $20.7 billion due to prior-year investment gains.

Term
Q3 2026

“Our AWS investment in functionality and infrastructure is working, with over 39% year-over-year revenue growth in Q3 ($184 billion revenue run rate) and projected revenue growth rates of over 40% both in 2027 and in 2028.”

Andy Jassy, President and CEO, Amazon

“Our broader selection and speedier delivery are helping us capture more retail market segment share with improving margins, and our newer businesses, ranging from Grocery to Pharmacy to Amazon Leo to Zoox are progressing encouragingly. There has never been a trillion dollar revenue business, and we may have two of them in the next 5-10 years.”

Andy Jassy, President and CEO, Amazon
4:06 PM ET 8-K
Financial Results Pure Bioscience, Inc. PURE

Pure Bioscience Financial Results

PURE Bioscience reported financial results for the fiscal year ended July 31, 2026, with net product sales increasing 5% to $2.3 million. The company posted a net loss of $2.5 million, or $0.02 per share, as growth in its end-user network was offset by a challenging macro environment and disruptions in the food industry.

Term
FY2026

“We are up year-over-year despite being a challenging year, with the macro environment causing increased expenses and foodborne outbreaks severely disrupting the food industry. Although our growth didn’t meet expectations, our focus remains on reducing costs and converting more opportunities into revenue.”

Jeff Kitchell, Chief Executive Officer
4:06 PM ET 10-Q
Financial Results Nwpx Infrastructure, Inc. NWPX

Nwpx Infrastructure Q3 2026 Results: Net Income $18.2M, Up 35.0% YoY

NWPX Infrastructure, Inc. reported strong growth for the third quarter of 2026, with net sales increasing to $179.4 million from $151.1 million in the prior year period. Net income rose significantly to $18.2 million, or $1.86 per diluted share, driven by higher gross profits and improved operating margins.

Key figure
Net income $18.2M · +35.0% YoY
4:06 PM ET 8-K
Loan & Debt Lafayette Square USA, Inc.

Lafayette Square USA $315M Debt Financing with ING Capital LLC

Lafayette Square USA, Inc. entered into Amendment No. 3 to its Senior Secured Revolving Credit Agreement to increase aggregate commitments from $300 million to $315 million. The amendment also increases the accordion provision to allow for potential future increases up to a total facility amount of $600 million.

Value
$315M
Counterparty
ING Capital LLC
4:06 PM ET 10-Q
Financial Results Penske Automotive Group, Inc. PAG

Penske Automotive Group Q3 2026 Results: Net Income $221M, Down 1.8% YoY

Penske Automotive Group reported total revenues of $8.4 billion for the third quarter of 2026, a 4.5% increase compared to the prior year. While net income attributable to common stockholders slightly decreased to $220.8 million ($3.36 per share), the company significantly expanded its footprint through $669.7 million in acquisitions during the first nine months of the year.

Key figure
Net income $221M · -1.8% YoY
4:06 PM ET 8-K
Financial Results Exponent Inc EXPO

Exponent Financial Results

Exponent reported third quarter 2026 financial results with total revenues increasing 18% to $173.7 million and net income rising to $30.9 million. The company saw strong demand for user research studies and reactive work in failure analysis across the chemical, consumer products, and transportation industries.

Term
Q3 2026

“Exponent delivered another strong quarter, with double-digit growth in revenues and earnings, reflecting continued demand for our specialized, integrated engineering and scientific expertise.”

Dr. Catherine Corrigan, Chief Executive Officer

“Our multidisciplinary scientists and engineers bring together deep domain expertise, scientific rigor, and an understanding of complex physical systems to help clients innovate with confidence, solve their most challenging problems, and manage high-consequence risk.”

Dr. Catherine Corrigan, Chief Executive Officer
4:06 PM ET 8-K
Financial Results Stoke Therapeutics, Inc. STOK

Stoke Therapeutics Financial Results

Stoke Therapeutics reported Q3 2026 financial results, highlighting a cash position of $358.8 million which is expected to fund operations into early 2028. The company provided clinical updates on its Phase 3 EMPEROR study for Dravet syndrome, with a data readout anticipated in Q3 2027 and a planned NDA submission in H2 2027.

Term
Q3 2026

“The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when the primary endpoint of change in major motor seizure frequency is measured and approximately 20 are through Week 52, the end of the treatment period. All 20 of these patients are continuing into the open-label extension period of the study and to date, no patients have discontinued treatment.”

Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics

“Our second clinical program, STK-002, targets the protein haploinsufficiency that causes ADOA and therefore may have the potential to improve vision in people living with this severe genetic disease that often leads to blindness. Dosing in the first two cohorts is complete and dosing in the third cohort is underway with the fourth cohort expected to follow in early 2027.”

Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics
4:06 PM ET 8-K/A
Divestiture Faraday Future Intelligent Electric Inc. FFAI

Faraday Future Intelligent Electric Divestiture to FF EAI Robotics Ecosystem Inc. for $10M

Faraday Future completed the disposition and reorganization of its robotics business into FF EAI Robotics Ecosystem Inc. (FFR) on October 23, 2026. In connection with the transaction, FFR secured a $10.0 million PIPE financing from two investors, while remaining a consolidated subsidiary of Faraday Future.

Value
$10M
Counterparty
FF EAI Robotics Ecosystem Inc.
4:06 PM ET 8-K
Other 8-K Filing Strategy Inc MSTR

Strategy Other 8-K Filing

Strategy Inc filed amended and restated certificates of designations for four series of its perpetual preferred stock (STRF, STRC, STRK, and STRD) to modify the dividend payment frequency. The amendments provide for regular dividends to have a daily record date and be payable on the following business day, without changing the overall dividend rates or total payment obligations.

4:06 PM ET 8-K
Leadership Change Umb Financial Corp UMBF

Umb Financial Leadership Change

Shannon A. Johnson will step down as Chief Administrative Officer to focus exclusively on her existing role as Chief Risk Officer, effective October 28, 2026. The company announced it will not fill the Chief Administrative Officer position, redistributing those responsibilities among existing management.

4:06 PM ET 8-K
Financial Results Forrester Research, Inc. FORR

Forrester Research Financial Results

Forrester Research reported Q3 2026 total revenues of $86.1 million and a GAAP net loss of $4.4 million. Despite the revenue decline, the company raised the low end of its full-year adjusted EPS guidance to $0.77-$0.82, citing business stabilization and new AI product launches.

Term
Q3 2026

“We continue to see stabilization of the business, with results above consensus, a strong stock buyback program, and prudent expense management. As a result, we are raising the low end of our guidance for 2026 earnings per share.”

George F. Colony, CEO and Chairman

“Our AI focus is deliberate and intentional, and we continue to advance our product roadmap, delivering new AI capabilities. This quarter, we unveiled a robust portfolio of new products including AI Access Plus, Team Solutions, and an integration with Claude.”

George F. Colony, CEO and Chairman
4:06 PM ET 8-K
Financial Results Columbia Sportswear Co COLM

Columbia Sportswear Financial Results

Columbia Sportswear reported Q3 2026 net sales of $962.6 million, a 2% increase year-over-year, and diluted EPS of $1.66. The company raised the low end of its full-year 2026 revenue and EPS guidance, citing improved trends in U.S. direct-to-consumer business and international momentum.

Term
Q3 2026

“We’re pleased to have delivered net sales and EPS growth exceeding our guidance for the third quarter. These results primarily reflected a portion of delayed Fall ’26 wholesale orders shipping earlier-than-expected, improved trends in our U.S. DTC business, and the continued momentum of our international business, despite challenging global macroeconomic conditions.”

Tim Boyle, Chairman and Chief Executive Officer

“While fourth quarter execution will be critical to our full year performance, better-than-expected third quarter performance combined with improving trends in our U.S. business and the shipment of remaining Fall ’26 global wholesale orders gives us the confidence to raise the low end of our full-year revenue and EPS guidance.”

Tim Boyle, Chairman and Chief Executive Officer
4:06 PM ET 8-K
M&A Deal Marketaxess Holdings Inc MKTX

Marketaxess Holdings M&A Deal with Intercontinental Exchange, Inc.

MarketAxess stockholders approved the company's acquisition by Intercontinental Exchange, Inc. (ICE) at a special meeting held on October 29, 2026. The transaction, which will result in MarketAxess becoming a wholly owned subsidiary of ICE, remains subject to regulatory approvals and is expected to close in the first quarter of 2027.

Counterparty
Intercontinental Exchange, Inc.
4:06 PM ET Form 4
Insider Buying Northpointe Bancshares Inc NPB

Northpointe Bancshares Insider Rajeev Kumar Chaudhary Buys $47.4K of Stock

Rajeev Kumar Chaudhary bought 3,000 shares of Northpointe Bancshares Inc at $15.80 a share, worth $47.4K in total on Oct 28, 2026. Shares held after the trade: 3,000.

Value
$47.4K
Shares
3,000
Price
$15.80
Trade date
Oct 28, 2026
4:06 PM ET 8-K
Dividend Bruker Corp BRKR

Bruker Dividend

Bruker Corporation's Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable on December 1, 2026, to shareholders of record as of November 15, 2026.

4:05 PM ET 8-K
M&A Deal Outdoor Specialty Products, Inc. ODRS

Outdoor Specialty Products Signs $1.5M M&A Deal with Quantum Qualified Opportunity Fund, LLC

Outdoor Specialty Products, Inc. entered into a Stock Purchase Agreement with Quantum Qualified Opportunity Fund, LLC, which will acquire a controlling interest in the company. Quantum will purchase 24,402,042 shares of common stock for $1.5 million in cash, while existing principal stockholders will exchange 4,000,000 common shares for newly authorized Series A Preferred Stock.

Value
$1.5M
Counterparty
Quantum Qualified Opportunity Fund, LLC
4:05 PM ET 10-Q
Financial Results Gen Digital Inc. GEN

Gen Digital Q2 2026 Results: Net Income $287M, Up 114.2% YoY

Gen Digital Inc. reported net revenues of $1,369 million for the quarter ended October 2, 2026, up from $1,220 million in the prior year period. Net income significantly increased to $287 million compared to $134 million, driven by higher gross profits and lower interest expenses.

Key figure
Net income $287M · +114.2% YoY
4:05 PM ET 8-K
Leadership Change General Motors Co GM

General Motors Leadership Change

Christopher T. Hatto, Vice President, Global Business Solutions and Chief Accounting Officer of General Motors, has notified the company of his decision to retire effective April 1, 2027. He will continue to serve as the principal accounting officer until his retirement date to ensure an orderly transition, and a successor has not yet been named.

4:05 PM ET 10-Q
Financial Results Middlesex Water Co MSEX

Middlesex Water Q3 2026 Results: Net Income $18M, Up 29.2% YoY

Middlesex Water Co reported a significant increase in net income for the nine months ended September 30, 2026, reaching $43.4 million compared to $34.2 million in the prior year period. Operating revenues grew by 11.9% year-over-year, driven by higher operating income, while the company continued to expand its utility plant assets to over $1.5 billion.

Key figure
Net income $18M · +29.2% YoY
4:05 PM ET 8-K
Financial Results Biohaven Ltd. BHVN

Biohaven Financial Results

Biohaven Ltd. reported third quarter 2026 financial results and provided updates on its clinical pipeline, including the FDA's acceptance of the NDA resubmission for troriluzole. The company highlighted significant regional licensing deals with SK Biopharmaceuticals and Ono Pharmaceutical, which are expected to provide substantial near-term cash consideration.

“This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value. We are excited to have entered into the first ever regional collaboration for an extracellular protein degrader with Ono Pharmaceutical to develop and commercialize our MoDE IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan and the ASEAN region.”

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven

“Establishing these unique collaborations with two leading global drug development and commercialization companies is a testament to the impressive potential and versatility of our portfolio.”

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
4:05 PM ET Form 4
Insider Buying Elevra Lithium Ltd ELVR

Elevra Lithium CFO Vargas Christian Mauricio Cortes Buys $42.7K of Stock

Vargas Christian Mauricio Cortes, CFO, bought 16,000 shares of Elevra Lithium Ltd at $2.67 a share, worth $42.7K in total on Oct 28, 2026.

Value
$42.7K
Shares
16,000
Average price
$2.67
Role
CFO
Trade date
Oct 28, 2026
4:05 PM ET 8-K
Court & Legal Update Enanta Pharmaceuticals Inc ENTA

Enanta Pharmaceuticals Court & Legal Update

The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4 051 265 is invalid, dismissing Enanta's patent infringement action against Pfizer. The lawsuit concerned Pfizer's manufacture and sale of Paxlovid in 18 EU member states. Enanta had sought a determination of liability for infringement, but the court found the infringement action unfounded following its decision on patent validity.

Counterparty
Pfizer Inc.
4:05 PM ET Form 4
Insider Selling Nasdaq, Inc. NDAQ

Nasdaq EVP, CIO Bradley J. Peterson Sells $418K of Stock

Bradley J. Peterson, EVP, CIO, sold 3,987 shares of Nasdaq, Inc. at $104.75 a share, worth $418K in total on Oct 27, 2026. Shares held after the trade: 114,306 (-3.4%).

Value
$418K
Shares
3,987
Price
$104.75
Role
EVP, CIO
Holding change
-3.4%
Trade date
Oct 27, 2026
4:05 PM ET 10-Q
Financial Results Ecolab Inc. ECL

Ecolab Q3 2026 Results: Net Income $551M, Down 5.8% YoY

Ecolab Inc. reported net sales of $4.69 billion for the third quarter of 2026, an increase from $4.17 billion in the prior year, though net income attributable to Ecolab decreased slightly to $551.3 million. The company's balance sheet showed significant growth in total assets to $31.1 billion, primarily driven by a substantial increase in goodwill and intangible assets following $4.68 billion in acquisition activity during the first nine months of the year.

Key figure
Net income $551M · -5.8% YoY
4:05 PM ET 10-Q
Financial Results CareDx, Inc. CDNA

CareDx Q3 2026 Results: Net Income $19.3M, Up 1051.8% YoY

CareDx reported a significant increase in total revenue to $389.0 million for the nine months ended September 30, 2026, compared to $271.4 million in the prior year. The company achieved a net income of $132.7 million during this period, primarily driven by a $113.0 million gain from the sale of its lab products business and strong growth in testing services revenue.

Key figure
Net income $19.3M · +1051.8% YoY
4:05 PM ET 8-K
Investor Presentation Spok Holdings, Inc SPOK

Spok Holdings Investor Presentation

Spok Holdings, Inc. has published an updated investor presentation for October 2026, which is incorporated into the filing as Exhibit 99.1. The presentation outlines the company's strategic focus on maximizing revenue and cash generation from its established businesses while returning capital to stockholders through dividends and share repurchases.

4:05 PM ET 8-K
Financial Results Pro Dex Inc PDEX

Pro Dex Financial Results

Pro-Dex, Inc. reported its fiscal 2027 first quarter results, with net sales increasing 11% to $20.6 million driven by medical device revenue growth. Net income decreased to $3.0 million from $4.7 million in the prior year, primarily due to a significant decrease in unrealized gains on marketable equity investments compared to the year-ago period.

Term
Q1 2027

“We are pleased with our first quarter results and continued top line revenue growth.”

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer

“We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.”

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer
4:05 PM ET 10-Q
Financial Results Biohaven Ltd. BHVN

Biohaven Q3 2026 Results: Net Loss of $129M, Loss Narrows

Biohaven Ltd. reported a net loss of $129.3 million for the third quarter of 2026, an improvement from the $173.4 million loss in the prior year period. The company continues to fund its clinical pipeline in immunology, obesity, and neuroscience, ending the period with $161.1 million in cash and marketable securities.

Key figure
Net loss $129M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.